Bipolar Spectrum Disorder: Differential Diagnosis and Treatment

Primary Care - Clinics in Office Practice

Volumn 34, Issue 3, 2007, Pages 521-550

  Muzina, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; LOOP DIURETIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PSYCHOTROPIC AGENT; PYRIDONE DERIVATIVE; QUETIAPINE; RISPERIDONE; THIAZIDE DIURETIC AGENT; TRANQUILIZER; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ACNE; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ATAXIA; BIPOLAR DISORDER; BLOOD DYSCRASIA; BLURRED VISION; BRADYCARDIA; CONFUSION; DELIRIUM; DEPRESSION; DIAGNOSTIC ERROR; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DIZZINESS; DRUG DOSE TITRATION; FAMILY HISTORY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HAIR DISEASE; HEADACHE; HEMORRHAGIC PANCREATITIS; HIGH RISK PATIENT; HUMAN; HYPERAMMONEMIA; HYPERREFLEXIA; HYPONATREMIA; LIPID BLOOD LEVEL; LIVER FAILURE; LOADING DRUG DOSE; MAJOR DEPRESSION; MENTAL HEALTH; METABOLIC DISORDER; MOOD DISORDER; MORBIDITY; MORTALITY; MYOCLONUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSONISM; PATIENT REFERRAL; POLYDIPSIA; POLYURIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIASIS; PSYCHIATRIST; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; SLURRED SPEECH; SOMNOLENCE; SUICIDE; SYNCOPE; TREMOR; VOMITING; WEIGHT GAIN;

ACUTE DISEASE; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; PRIMARY HEALTH CARE; SUICIDE;

EID: 34548512219     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2007.06.001     Document Type: Review

References (69)

1. Kraepelin E. Manic-depressive insanity and paranoia (1921), Livingstone E&S, Edinburgh (Scotland)
2. Angst J., and Marneros A. Bipolarity from ancient to modern times: conception, birth and rebirth. J Affect Disord 67 1-3 (2001) 3-19
3. Regier D.A., Narrow W.E., Rae D.S., et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 50 2 (1993) 85-94
4. Manning J.S. Difficult-to-treat depressions: a primary care perspective. J Clin Psychiatry 64 Suppl 1 (2003) 24-31
5. Manning J.S., Haykal R.F., Connor P.D., et al. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 38 2 (1997) 102-108
6. Regier D.A., Farmer M.E., Rae D.S., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264 19 (1990) 2511-2518
7. Hirschfeld R.M., Calabrese J.R., Weissman M.M., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 64 1 (2003) 53-59
8. Merikangas K.R., Akiskal H.S., Angst J., et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 64 5 (2007) 543-552
9. Calabrese J.R., Muzina D.J., Kemp D.E., et al. Predictors of bipolar disorder risk among patients currently treated for major depression. MedGenMed 8 3 (2006) 38
10. Hirschfeld R.M., Cass A.R., Holt D.C., et al. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 18 4 (2005) 233-239
11. Akiskal H.S., Bourgeois M.L., Angst J., et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 59 Suppl 1 (2000) S5-S30
12. Benazzi F., and Akiskal H.S. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord 73 1-2 (2003) 33-38
13. Hantouche E.G., Akiskal H.S., Lancrenon S., et al. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 50 2-3 (1998) 163-173
14. Diagnostic and statistical manual of mental disorders. 4th edition (1994), American Psychiatric Association, Washington, DC
15. Akiskal H.S., Djenderedjian A.M., Rosenthal R.H., et al. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry 134 11 (1977) 1227-1233
16. Rihmer Z., and Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 22 3 (1999) 667-673 ix-x
17. Ghaemi S.N., Hsu D.J., Ko J.Y., et al. Bipolar spectrum disorder: a pilot study. Psychopathology 37 5 (2004) 222-226
18. Judd L.L., and Akiskal H.S. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep 5 6 (2003) 417-418
19. Judd L.L., Schettler P.J., Akiskal H.S., et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 6 2 (2003) 127-137
20. Lish J.D., Dime-Meenan S., Whybrow P.C., et al. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 31 4 (1994) 281-294
21. Hirschfeld R.M., Lewis L., and Vornik L.A. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 64 2 (2003) 161-174
22. Access Economics. Bipolar disorder: costs. An analysis of the burden of bipolar disorder and related suicide in Australia. Melbourne. Available at: http://www.sane.org/images/stories/information/research/0505_info_bpcosts.pdf. Accessed July 2007.
23. Muzina D.J., Colangelo E., Manning J.S., et al. Differentiating bipolar disorder from depression in primary care. Cleve Clin J Med 74 2 (2007) 89-99
24. Frye M.A., Calabrese J.R., Reed M.L., et al. Use of health care services among persons who screen positive for bipolar disorder. Psychiatr Serv 56 12 (2005) 1529-1533
25. Ghaemi S.N., Boiman E.E., and Goodwin F.K. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 61 10 (2000) 804-808 [quiz: 809]
26. Leverich G.S., Altshuler L.L., Frye M.A., et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 163 2 (2006) 232-239
27. Woods S.W. The economic burden of bipolar disease. J Clin Psychiatry 61 Suppl 13 (2000) 38-41
28. Begley C.E., Annegers J.F., Swann A.C., et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 19 5 Pt 1 (2001) 483-495
29. Goodwin F.K., and Jamison K.R. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd edition (2007), Oxford University Press Inc, New York
30. Guze S.B., and Robins E. Suicide and primary affective disorders. Br J Psychiatry 117 539 (1970) 437-439
31. Dutta R., Boydell J., Kennedy N., et al. Suicide and other causes of mortality in bipolar disorder: a longitudinal study. Psychol Med 37 6 (2007) 839-847
32. Willour V.L., Zandi P.P., Badner J.A., et al. Attempted suicide in bipolar disorder pedigrees: evidence for linkage to 2p12. Biol Psychiatry 61 5 (2007) 725-727
33. Valtonen H.M., Suominen K., Mantere O., et al. Suicidal behaviour during different phases of bipolar disorder. J Affect Disord 97 1-3 (2007) 101-107
34. Muzina D.J. What physicians can do to prevent suicide. Cleve Clin J Med 71 3 (2004) 242-250
35. Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry 20 1 (2007) 17-22
36. Manning J.S., Haykal R.F., and Akiskal H.S. The role of bipolarity in depression in the family practice setting. Psychiatr Clin North Am 22 3 (1999) 689-703 x
37. Das A.K., Olfson M., and Gameroff M.J. Screening for bipolar disorder in a primary care practice. JAMA 293 (2005) 956-963
38. Ettinger A.B., Reed M.L., Goldberg J.F., et al. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 65 4 (2005) 535-540
39. Parrisbalogun-Cole S, Wilke W, Muzina DJ. Screening for bipolar disorder in fibromyalgia clinic. Paper presented at the 7th International Conference on Bipolar Disorder. Pittsburgh (PA), June 7-9, 2007.
40. Sachs G.S., Nierenberg A.A., Calabrese J.R., et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356 17 (2007) 1711-1722
41. Amador X.F., Flaum M., Andreasen N.C., et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 51 10 (1994) 826-836
42. Keitner G.I., Solomon D.A., Ryan C.E., et al. Prodromal and residual symptoms in bipolar I disorder. Compr Psychiatry 37 5 (1996) 362-367
43. Hirschfeld R.M., Williams J.B., Spitzer R.L., et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 157 11 (2000) 1873-1875
44. Wagner K.D., Hirschfeld R.M., Emslie G.J., et al. Validation of the Mood Disorder Questionnaire for bipolar disorders in adolescents. J Clin Psychiatry 67 5 (2006) 827-830
45. Ghaemi S.N., Miller C.J., Berv D.A., et al. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect Disord 84 2-3 (2005) 273-277
46. Weissman M.M., Bland R.C., Canino G.J., et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 4 (1996) 293-299
47. Joyce P.R., Doughty C.J., Wells J.E., et al. Affective disorders in the first-degree relatives of bipolar probands: results from the South Island Bipolar Study. Compr Psychiatry 45 3 (2004) 168-174
48. McIntyre R.S., Konarski J.Z., Soczynska J.K., et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 57 8 (2006) 1140-1144
49. McIntyre R.S., Konarski J.Z., Wilkins K., et al. The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache 46 6 (2006) 973-982
50. Hantouche E.G., and Akiskal H.S. Bipolar II vs. unipolar depression: psychopathologic differentiation by dimensional measures. J Affect Disord 84 2-3 (2005) 127-132
51. Suppes T., Dennehy E.B., Hirschfeld R.M., et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66 7 (2005) 870-886
52. Yatham L.N., Kennedy S.H., O'Donovan C., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 7 Suppl 3 (2005) 5-69
53. Rosa A.R., Marco M., Fachel J.M., et al. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Prog Neuropsychopharmacol Biol Psychiatry 31 1 (2007) 217-224
54. Laborit H., Huguenard P., and Alluaume R. [A new vegetative stabilizer; 4560 R.P.]. Presse Med 60 10 (1952) 206-208 [in French]
55. Litchfield H.R. Aminophenylpyridone, a new mood-stabilizing drug. Arch Pediatr 77 (1960) 133-137
56. Bauer M.S., and Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 161 1 (2004) 3-18
57. Hirschfeld R.M., Bowden C.L., Gitlin M.J., et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 (2002) 1-50
58. Sachs G.S. Bipolar disorder clinic synthesis: where does the evidence lead?. Focus V 1 (2007) 1-11
59. Ghaemi S.N., and Thase M.E. Role of antiepileptics and atypical antipsychotics-bipolar depression. Current Psychiatry 1 (2002) 13-20
60. Calabrese J.R., Bowden C.L., Sachs G.S., et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 60 2 (1999) 79-88
61. Prien R.F., Kupfer D.J., Mansky P.A., et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41 11 (1984) 1096-1104
62. Perlis R.H., Welge J.A., Vornik L.A., et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 67 4 (2006) 509-516
63. Kemp D.E., Gilmer W.S., Fleck J., et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 31 2 (2007) 574-577
64. McElroy S.L., Suppes T., Frye M.A., et al. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord 101 1-3 (2007) 275-281
65. Sokolski K.N. Adjunctive aripiprazole in bipolar I depression. Ann Pharmacother 41 1 (2007) 35-40
66. Post R.M., Uhde T.W., Putnam F.W., et al. Kindling and carbamazepine in affective illness. J Nerv Ment Dis 170 12 (1982) 717-731
67. Muzina D.J., Elhaj O., Gajwani P., et al. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand Suppl 426 (2005) 21-28
68. Muzina D.J., Gajwani P., Kemp D.E., et al. Antiepileptic drugs for acute bipolar depression: applying data to clinical practice. Psychiatr Ann 36 9 (2006) 637-644
69. Calabrese J.R., Sullivan J.R., Bowden C.L., et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 63 11 (2002) 1012-1019